Benjamin Levy

7.1k total citations
97 papers, 1.9k citations indexed

About

Benjamin Levy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Benjamin Levy has authored 97 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Benjamin Levy's work include Lung Cancer Treatments and Mutations (66 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Lung Cancer Research Studies (31 papers). Benjamin Levy is often cited by papers focused on Lung Cancer Treatments and Mutations (66 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Lung Cancer Research Studies (31 papers). Benjamin Levy collaborates with scholars based in United States, Spain and Canada. Benjamin Levy's co-authors include Daniel Becker, Josephine Feliciano, Medha S. Darshan, Daniel Escuín, Ada Gjyrezi, Matthew S. Loftus, Scott T. Tagawa, Ruoqian Shen, Chantal Chanel‐Vos and Maria Thadani‐Mulero and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Benjamin Levy

91 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Levy United States 23 1.1k 966 526 503 197 97 1.9k
Harpreet Singh United States 24 647 0.6× 1.0k 1.1× 495 0.9× 427 0.8× 128 0.6× 101 1.8k
Jessica Menis Italy 21 1.1k 1.0× 1.2k 1.2× 381 0.7× 363 0.7× 185 0.9× 76 1.9k
John R. Goffin Canada 24 833 0.7× 988 1.0× 765 1.5× 560 1.1× 144 0.7× 72 2.3k
Alex Friedlaender Switzerland 28 1.1k 1.0× 1.5k 1.5× 711 1.4× 437 0.9× 140 0.7× 86 2.3k
Yazdi K. Pithavala United States 25 1.2k 1.1× 1.1k 1.1× 1.2k 2.2× 581 1.2× 153 0.8× 65 2.5k
Erika Rijavec Italy 24 707 0.6× 1.1k 1.1× 489 0.9× 420 0.8× 132 0.7× 93 1.7k
Guillermo López-Vivanco Spain 21 1.0k 0.9× 1.3k 1.3× 677 1.3× 405 0.8× 139 0.7× 116 2.1k
Umang Swami United States 21 634 0.6× 727 0.8× 468 0.9× 282 0.6× 179 0.9× 173 1.6k
Nicola Battelli Italy 23 814 0.7× 1.0k 1.1× 512 1.0× 553 1.1× 180 0.9× 91 1.9k
Daniel T. Milton United States 16 1.9k 1.6× 1.6k 1.7× 587 1.1× 383 0.8× 128 0.6× 27 2.4k

Countries citing papers authored by Benjamin Levy

Since Specialization
Citations

This map shows the geographic impact of Benjamin Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Levy more than expected).

Fields of papers citing papers by Benjamin Levy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Levy. The network helps show where Benjamin Levy may publish in the future.

Co-authorship network of co-authors of Benjamin Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Levy. A scholar is included among the top collaborators of Benjamin Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Levy. Benjamin Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marrone, Kristen A., Joseph C. Murray, Josephine Feliciano, et al.. (2025). Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases. Journal of Neuro-Oncology. 175(2). 561–569.
2.
Galiatsatos, Panagis, et al.. (2024). Psoralen: a narrative review of current and future therapeutic uses. Journal of Cancer Research and Clinical Oncology. 150(3). 130–130. 16 indexed citations
3.
4.
Anagnostou, Valsamo, Cheryl Ho, Garth Nicholas, et al.. (2023). ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. 29(10). 2559–2569. 66 indexed citations
5.
Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113. 6 indexed citations
6.
7.
Hazell, Sarah Z., Wei Fu, Peijin Han, et al.. (2020). Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram. Clinical Lung Cancer. 21(6). e622–e632. 8 indexed citations
8.
Levy, Benjamin, Luis Paz‐Ares, Jaafar Bennouna, et al.. (2019). Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer. 20(3). e407–e412. 8 indexed citations
9.
Levy, Benjamin, Giuseppe Giaccone, Benjamin Besse, et al.. (2019). Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer. 108. 120–128. 48 indexed citations
10.
McCoach, Caroline E., Collin M. Blakely, Kimberly C. Banks, et al.. (2018). Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(12). 2758–2770. 114 indexed citations
11.
Ahluwalia, Manmeet S., et al.. (2018). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. The Oncologist. 23(10). 1199–1209. 44 indexed citations
12.
Yang, Hongyan, Benjamin Levy, James Signorovitch, et al.. (2018). 181P Real-world comparative effectiveness of treatment sequences in metastatic non-small cell lung cancer with squamous histology. Journal of Thoracic Oncology. 13(4). S108–S108. 1 indexed citations
13.
Suresh, Karthik, Kevin J. Psoter, Khinh Ranh Voong, et al.. (2018). Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. Journal of Thoracic Oncology. 14(3). 494–502. 109 indexed citations
14.
Reck, Martin, Marina Chiara Garassino, Martina Imbimbo, et al.. (2018). Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 120. 62–69. 23 indexed citations
15.
Socinski, Mark A., Jamie E. Chaft, Benjamin Levy, et al.. (2017). The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. Clinical Lung Cancer. 18(3). 255–258. 2 indexed citations
16.
Veluswamy, Rajwanth, Benjamin Levy, & Juan P. Wisnivesky. (2016). Chemotherapy in elderly patients with nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine. 22(4). 336–343. 11 indexed citations
17.
Saxena, Ashish, et al.. (2015). Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. The Oncologist. 20(8). 934–945. 31 indexed citations
18.
Darshan, Medha S., Matthew S. Loftus, Maria Thadani‐Mulero, et al.. (2011). Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. Cancer Research. 71(18). 6019–6029. 343 indexed citations
19.
Levy, Benjamin, Jon Arnason, & James B. Bussel. (2008). The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. Current Opinion in Oncology. 20(6). 690–696. 14 indexed citations
20.
Levy, Benjamin, John F. Deeken, Gregory E. Holt, & John L. Marshall. (2005). Immunologic Therapies for Gastrointestinal Cancers. Clinical Colorectal Cancer. 5(1). 37–49. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harpreet Singh Breakdown of academic impact, for papers by Jessica Menis Breakdown of academic impact, for papers by John R. Goffin Breakdown of academic impact, for papers by Alex Friedlaender Breakdown of academic impact, for papers by Yazdi K. Pithavala Breakdown of academic impact, for papers by Erika Rijavec Breakdown of academic impact, for papers by Guillermo López-Vivanco Breakdown of academic impact, for papers by Umang Swami Breakdown of academic impact, for papers by Nicola Battelli Breakdown of academic impact, for papers by Daniel T. Milton
Rankless by CCL
2026